Fexinidazole

Major

Fexinidazole Felbamate Felbatol An increased risk of QT interval prolongation Details Fexinidazole Felodipine Plendil® An increased CYP3A4 substrate exposure Details Fexinidazole Fentanyl Transdermal Patch Duragesic® An increased CYP3A4 substrate exposure Details Fexinidazole Finerenone Kerendia An increased CYP3A4 substrate exposure Details Fexinidazole Flecainide Tambocor® An increased risk of QT interval prolongation Details Fexinidazole Foscarnet Injection Foscavir An increased risk of QT interval prolongation Details Fexinidazole Fostamatinib Tavalisse An increased CYP3A4 substrate exposure Details Fexinidazole Fostemsavir Rukobia An increased CYP3A4 substrate exposure Details Fexinidazole Furosemide Injection Disal Increased exposure of OAT1/OAT3 substrate Details Fexinidazole Galantamine Razadyne An increased risk of QT interval prolongation Details Fexinidazole Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation Details Fexinidazole Gemifloxacin Factive An increased risk of QT interval prolongation Details Fexinidazole Gilteritinib Xospata An increased CYP3A4 substrate exposure Details Fexinidazole Glasdegib Daurismo Increased exposure of CYP3A4 substrate; increased risk of QT interval prolongation and arrhythmias Details Fexinidazole Goserelin Implant Zoladex An increased risk of QT interval prolongation Details Fexinidazole Granisetron Transdermal Patch Sancuso An increased risk of QT interval prolongation Details Fexinidazole Granisetron Injection Granisol An increased risk of QT interval prolongation Details Fexinidazole Guanfacine Intuniv An increased CYP3A4 substrate exposure Details Fexinidazole Histrelin Implant Supprelin An increased risk of QT interval prolongation Details Fexinidazole Hydrocortisone Ala-Cort An increased CYP3A4 substrate exposure Details Fexinidazole Hydrocortisone Injection A-Hydrocort® An increased CYP3A4 substrate exposure Details Fexinidazole Hydroxychloroquine Plaquenil An increased risk of QT interval prolongation Details Fexinidazole Ibrexafungerp Brexafemme An increased CYP3A4 substrate exposure Details Fexinidazole Ibrutinib Imbruvica An increased CYP3A4 substrate exposure Details Fexinidazole Ifosfamide Injection Ifex Possible altered exposure of ifosfamide Details Fexinidazole Inotuzumab Ozogamicin Injection Besponsa An increased risk of QT interval prolongation Details Fexinidazole Irinotecan Camptosar An increased CYP3A4 substrate exposure Details Fexinidazole Irinotecan Injection Camptosar An increased CYP3A4 substrate exposure Details Fexinidazole Irinotecan Lipid Complex Injection Onivyde® An increased CYP3A4 substrate exposure Details Fexinidazole Istradefylline Nourianz An increased CYP3A4 substrate exposure Details Fexinidazole Ivabradine Corlanor Increased exposure of CYP3A4 substrate; increased risk of QT interval prolongation and arrhythmias Details Fexinidazole Ixazomib Ninlaro An increased CYP3A4 substrate exposure Details Fexinidazole Ketoconazole Topical Extina® Foam Increased risk of QT interval prolongation Details Fexinidazole Labetalol Normodyne® Increased risk of bradycardia Details Fexinidazole Lefamulin Xenleta An increased risk of QT interval prolongation Details Fexinidazole Lenvatinib Lenvima An increased risk of QT interval prolongation Details Fexinidazole Letermovir Injection Prevymis Reduced exposure of active fexinidazole metabolites and potential decreased efficacy of fexinidazole Details Fexinidazole Levofloxacin Levaquin An increased risk of QT interval prolongation Details Fexinidazole Levofloxacin Injection Levaquin An increased risk of QT interval prolongation Details Fexinidazole Loperamide Diamode An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details